

## Vernakalant (CCU)

<b>Indication</b>	Terminate Atrial Fibrillation			
<b>Form</b>	500mg per 25mL vial (20mg/mL)			
<b>Reconstitution</b>	Already in solution <b>Further dilute before administration</b>			
<b>Compatibility &amp; Stability</b>	Sodium chloride 0.9% Glucose 5%			
<b>Administration</b>	<b>IV Infusion</b>			
	<b>Patient weight</b>	<b>Volume of concentrated vernakalant</b>	<b>Volume of diluent (N/Saline)</b>	<b>Final volume of diluted solution</b>
	≤100kg	25mL	100mL	125mL
	>100kg	30mL	120mL	150mL
	Initial Infusion: 3mg/kg infused over 10 mins (Max 339mg) Second infusion (if needed): 2mg/kg infused over 10 min (Max 226mg)			
	<b>See Protocol for the administration of Vernakalant (Brinavess™)</b>			
<b>Monitoring</b>	<ul style="list-style-type: none"> <li>Vernakalant can cause hypotension in patients so it is recommended to prehydrate patients with 500mL sodium chloride 0.9%.</li> <li>In patients with uncorrected hypokalaemia (serum potassium of less than 3.5 mmol/L), potassium levels should be corrected prior to use of vernakalant.</li> <li>Cases of serious hypotension have been reported during and immediately following vernakalant infusion. Patients should be carefully observed for the entire duration of the infusion and for at least 15 minutes after completion of the infusion with assessment of vital signs and continuous cardiac rhythm monitoring.</li> </ul>			
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>The diluted sterile solution should be clear, colourless to pale yellow. The solution should be visually re-inspected for particulate matter and discolouration before administering.</li> </ul>			

Information relates to Brinavess™ manufactured by Correvio

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542*